The liver toxicity biomarker study: phase I design and preliminary results.

  title={The liver toxicity biomarker study: phase I design and preliminary results.},
  author={Robert N. McBurney and Wade M. Hines and Linda S Von Tungeln and Laura K. Schnackenberg and Richard D. Beger and Carrie L. Moland and Tao Han and James C. Fuscoe and Ching-Wei Chang and James J. Chen and Zhenqiang Su and Xiao-hui Fan and Weida Tong and Shelagh A Booth and Raji Balasubramanian and Paul L Courchesne and Jennifer M Campbell and Armin Graber and Y. A. Guo and Peter J Juhasz and Tricin Y Li and Moira D Lynch and Nicole M Morel and Thomas N Plasterer and Edward J Takach and Chenhui Zeng and Frederick A Beland},
  journal={Toxicologic pathology},
  volume={37 1},
Drug-induced liver injury (DILI) is the primary adverse event that results in withdrawal of drugs from the market and a frequent reason for the failure of drug candidates in development. The Liver Toxicity Biomarker Study (LTBS) is an innovative approach to investigate DILI because it compares molecular events produced in vivo by compound pairs that (a) are similar in structure and mechanism of action, (b) are associated with few or no signs of liver toxicity in preclinical studies, and (c… CONTINUE READING